阿斯利康AstraZeneca（AZN）2025年第四季度及全年业绩报告「LSE」（英文版）（39页）.pdf

1、Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 1 10 February 2026 AstraZeneca results:FY and Q4 2025 Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period Revenue and EPS summary FY 2025%Change Q4 2

2、025%Change$m Actual CER1$m Actual CER -Product Sales 55,573 9 9 14,538 9 7 -Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89)(89)6 (99)(99)Total Revenue 58,739 9 8 15,503 4 2 Reported EPS($)6.60 45 43 1.50 55 47 Core3 EPS($)9.16 12 11 2.12

3、 1 (2)Key performance elements for FY 2025(Growth numbers at constant exchange rates)Total Revenue up 8%to$58,739m,driven by Oncology,CVRM,R&I and Rare Disease Growth in Total Revenue across all major geographic regions Core Operating profit increased 9%Core EPS increased 11%to$9.16 Second interim d

4、ividend declared of$2.17 per share(159.5 pence,19.49 SEK).Total dividend declared for FY 2025 increased by 3%to$3.20 per share 16 positive Phase 3 readouts and 43 approvals in major regions in the last twelve months Pascal Soriot,Chief Executive Officer,AstraZeneca,said:“In 2025 we saw strong commer

5、cial performance across our therapy areas and excellent pipeline delivery.We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phas

6、e 3 trial readouts this year.We have more than 100 Phase 3 studies ongoing,including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.Lastly,ordinary shares in our compa